Rundu Co., Ltd. announced that the company recently received the “Notice of Approval of Application for the Marketing of Chemical Ingredients” for levamlodipine benzenesulfonate issued by the State Drug Administration. The drug complies with the relevant requirements for drug registration and has been approved for registration. The indications are the treatment of high blood pressure and angina pectoris. This approval further improves the company's product layout in the field of cardiovascular and cerebrovascular treatment, enriches the product matrix, and helps enhance overall market competitiveness. There is uncertainty about the future sales situation of this drug. Investors are kindly requested to pay attention to investment risks.

Rundu Co., Ltd. announced that the company recently received the “Notice of Approval of Application for the Marketing of Chemical Ingredients” for levamlodipine benzenesulfonate issued by the State Drug Administration. The drug complies with the relevant requirements for drug registration and has been approved for registration. The indications are the treatment of high blood pressure and angina pectoris. This approval further improves the company's product layout in the field of cardiovascular and cerebrovascular treatment, enriches the product matrix, and helps enhance overall market competitiveness. There is uncertainty about the future sales situation of this drug. Investors are kindly requested to pay attention to investment risks.